87% of Women Experience Hair Loss, Only 25% Act on It. Kenvue's Scalp-First Playbook
Kenvue, the consumer health company behind Neutrogena and OGX, is moving to redefine women’s hair loss as a mass-market scalp-care category in 2026. The strategic thesis is blunt. Roughly 87% of women report experiencing hair loss, only 25% actually address it, and fewer than one in five of that group is satisfied with the result.
The Numbers Behind the Category
Kenvue frames that 87-25-20 chain as “white space.” Three out of four women who notice hair loss never act on it, and among those who do, 80% remain unsatisfied. The hair loss category has historically been built around androgenetic alopecia in men, leaving women under-served on price, access, and solution fit.
Two Lines, Walmart First, National Rollout
In November 2025, Kenvue launched Neutrogena Hair Restore and OGX ProGrowth + Peptide at Walmart, with national US retail rollout planned for 2026.
The formulations center on peptides and scalp science. Kenvue built these with in-house dermatologists and trichologists, working from the premise that follicle health is an extension of scalp skin health. The concrete move is porting peptide ingredients from skincare into scalp serums and shampoos.
The “Skinification of Hair”
Kenvue uses the term skinification of hair, meaning the ingredient-first approach that shaped skincare (niacinamide, peptides, salicylic acid, bakuchiol) is now restructuring haircare. In 2026, ingredient-led scalp serums are arriving on mass retail shelves.
This pattern has played out in Korea for years. Korean consumers are already familiar with “scalp ampoules” and “scalp boosters.” What changes in 2026 is that the US is extending that category to Walmart-scale mass distribution.
Cosmetic Boundaries, Medical Limits
Kenvue’s peptide lines are cosmetics, not drugs. First-line treatment for female pattern hair loss remains 2% topical minoxidil, with low-dose oral minoxidil seeing expanded off-label use since 2022. Kenvue’s products do not replace these therapies. They manage the day-to-day scalp environment.
That environment includes follicular exfoliation, scalp inflammation control, peri-follicular microcirculation, and surface conditioning of the hair fiber. Paired with minoxidil, a cleaner scalp environment can support more consistent drug absorption and effect, which is the standard trichologist observation.
Why the Gap Persists
Several structural reasons explain the 87%-to-25% drop-off. First, female hair loss typically shows as diffuse thinning across the crown rather than the M-shaped recession that makes male pattern loss visually obvious, so recognition comes late. Second, postpartum, stress-related, and diet-induced loss overlap, making attribution difficult. Third, hair loss clinics were historically designed for male patients, and women have reported discomfort with the consultation environment.
Kenvue’s mass-retail play attacks the access problem specifically. Buying a peptide scalp serum off a Walmart shelf reframes hair loss as a daily routine rather than a clinic visit.
What This Signals Globally
Korea already has a mature ingredient-led scalp care market, but Kenvue’s move carries two signals for consumers elsewhere. First, major global CPG companies are now reclassifying women’s hair loss as its own category. Second, peptide and niacinamide formulations familiar from skincare are becoming the default in haircare.
The habit of reading an ingredient list, long established in skincare, is crossing into shampoo and serum aisles. The question is shifting from “does it smell good” to “what peptide, at what concentration.”